| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Dec, 2022 | Dec, 2023 | Jun, 2023 |
| Sales | 1,930 | 1,940 | 2,130 | 1,500 | 2,230 |
| Sales Growth | -0.52% | -8.92% | +42.00% | -32.74% | +10.95% |
| Net Income | -21,920 | -18,600 | -24,490 | -16,880 | -21,300 |
| Net Income Growth | -17.85% | +24.05% | -45.08% | +20.75% | unch |
Mesoblast Ltd ADR (MESO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Fiscal Year End Date: 06/30